Prior to its acquisition and integration into Azurity Pharmaceuticals, Arbor Pharmaceuticals was led by Ed Schutter, who served as the long-standing President and Chief Executive Officer. During his tenure, Schutter directed the commercial growth and portfolio expansion of the specialty pharmaceutical company, building a robust pipeline focused on central nervous system disorders, cardiovascular therapies, and pediatric treatments, culminating in the company's transition into a wholly owned subsidiary of Azurity.